# A Study of Zasocitinib (TAK-279) in Adults With Active Crohn's Disease

> **NCT07403968** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Takeda** · enrollment: 20 (estimated)

## Conditions studied

- Crohn's Disease

## Interventions

- **DRUG:** Zasocitinib

## Key facts

- **NCT ID:** NCT07403968
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-29
- **Primary completion:** 2028-03-30
- **Final completion:** 2028-03-30
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07403968

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07403968, "A Study of Zasocitinib (TAK-279) in Adults With Active Crohn's Disease". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT07403968. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*